MARKET NEWS

View More News
English
Specials

Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
Webinar :Join an expert panel for a webinar on Smart investments for a secure retirement January 28, 2021. Register now!
you are here: HomeNewsBusinessMoneycontrol Research
  
  1
Last Updated Last Updated : August 03, 2020 / 01:35 PM IST | Source: Moneycontrol.com

Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

What adds to the Sun Pharma's investment case is the prospect for US specialty. The management hopes to achieve EBITDA break-even for a few products next fiscal

Anubhav Sahu

To view the full content of this article, you have to be a Pro:

  • Already a Moneycontrol Pro subscriber?
    Login now »
    Or
    Open in App
  • Not a Moneycontrol Pro subscriber yet?

Subscribe to Moneycontrol Pro:

What's included:

  • Ad free experience across Platforms
  • 230+ exclusive stories per month
  • Sharpest Opinions & Actionable Insights
  • Exclusive Research & Expert Technical Analysis
  • Daily Newsletter
  • 20+ Technical Picks every week
  • Recovery Tracker
  • Exclusive webinars on varied topics
  • Weekly wrap up and much more!!!
Subscribe to PRO and get unlimited access to premium content at Rs.33/- per month. Use code SUPERPRO